Retraction notice to 'The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells' [EBioMedicine 35 (2018) 204-221].
作者信息
Guo Jiwei, Jin Dan, Wu Yan, Yang Lijuan, Du Jing, Gong Kaikai, Chen Weiwei, Dai Juanjuan, Miao Shuang, Xi Sichuan
机构信息
Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China.
Department of Pain Management, Binzhou Medical University Hospital, Binzhou 256603, PR China.
出版信息
EBioMedicine. 2021 Jan;63:103168. doi: 10.1016/j.ebiom.2020.103168.
Abstract
摘要
相似文献
1
Retraction notice to 'The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells' [EBioMedicine 35 (2018) 204-221].撤回通知：“miR 495 - UBE2C - ABCG2/ERCC1轴通过下调顺铂耐药非小细胞肺癌细胞中的耐药基因逆转顺铂耐药性”[《电子生物医学》35 (2018) 204 - 221]
EBioMedicine. 2021 Jan;63:103168. doi: 10.1016/j.ebiom.2020.103168.
2
The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.miR-495-UBE2C-ABCG2/ERCC1 轴通过下调顺铂耐药非小细胞肺癌细胞中的耐药基因逆转顺铂耐药性。
EBioMedicine. 2018 Sep;35:204-221. doi: 10.1016/j.ebiom.2018.08.001. Epub 2018 Aug 23.
3
UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells.UBE2C通过ZEB1/2依赖性上调非小细胞肺癌细胞中的ABCG2和ERCC1诱导顺铂耐药。
J Oncol. 2019 Jan 1;2019:8607859. doi: 10.1155/2019/8607859. eCollection 2019.
4
Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149.组蛋白去乙酰化酶抑制剂通过调控miR-149使ERCC1高表达的非小细胞肺癌细胞对顺铂敏感。
Mol Ther Oncolytics. 2020 May 8;17:448-459. doi: 10.1016/j.omto.2020.05.001. eCollection 2020 Jun 26.
5
Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.UBE2C 的耗竭通过下调 CDK1 降低卵巢癌恶性程度并逆转顺铂耐药性。
Biochem Biophys Res Commun. 2020 Mar 5;523(2):434-440. doi: 10.1016/j.bbrc.2019.12.058. Epub 2019 Dec 23.
6
[The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].[miR-503对A549/DDP细胞顺铂耐药的逆转作用及分子机制]
Zhongguo Fei Ai Za Zhi. 2014 Jan;17(1):1-7. doi: 10.3779/j.issn.1009-3419.2014.01.01.
7
Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.慢病毒介导的靶向ERCC1的RNA干扰沉默可逆转顺铂耐药卵巢癌细胞系的顺铂耐药性。
DNA Cell Biol. 2015 Jul;34(7):497-502. doi: 10.1089/dna.2015.2805. Epub 2015 May 5.
8
Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.熊果酸通过抑制缺氧诱导因子-1α的表达下调 ABCG2，从而抑制卵巢癌干细胞的增殖并逆转其耐药性。
Oncol Rep. 2016 Jul;36(1):428-40. doi: 10.3892/or.2016.4813. Epub 2016 May 18.
9
Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.舌鳞状细胞癌中miR-222-ABCG2调控模块的失调导致化疗耐药并增强迁移/侵袭潜能。
Oncotarget. 2015 Dec 29;6(42):44538-50. doi: 10.18632/oncotarget.6253.
10
Retraction notice to " HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells" [eBioMedicine 48 (2019) 117 - 129].撤回声明：“HBV编码的miR-2通过下调TRIM35但上调RAN在肝癌细胞中发挥癌基因作用”[《电子生物医学》48卷（2019年）第117 - 129页]
EBioMedicine. 2021 Oct;72:103667. doi: 10.1016/j.ebiom.2021.103667.
引用本文的文献
1
Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.下调 GRP78 通过 miR-495-3p 模拟物逆转三阴性乳腺癌的吡柔比星耐药性，涉及 p-AKT/mTOR 通路。
Biosci Rep. 2022 Jan 28;42(1). doi: 10.1042/BSR20210245.
本文引用的文献
1
The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.miR-495-UBE2C-ABCG2/ERCC1 轴通过下调顺铂耐药非小细胞肺癌细胞中的耐药基因逆转顺铂耐药性。
EBioMedicine. 2018 Sep;35:204-221. doi: 10.1016/j.ebiom.2018.08.001. Epub 2018 Aug 23.
Zotero 插件